Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets...
healthy pullback with a run up to the .5 area followed by a pullback for a double bottom. bullish volume confirmed, long positon and call option position open. nice run to $5 area.
CHRS: Junshi Biosciences 2021-12-13 07:00:00 Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
CHRS: Coherus BioSciences, Inc. 2021-11-15 08:30:00 Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
Rated by CNBC as one of the three stocks most vulnerable to a squeeze. Will see))
COHERUS BIOSCIENCES Inc., NASDAQ:CHRS , is a bioscience company that has not yet not benefited from the sector's outperformance despite significantly improving financials and the business becoming profitable. When the stock price cracks the $21 level it will unlock a significant bullish potential.
This is a signal that CHRS's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. Tickeron A.I.dvisor identified 63 similar cases where CHRS's stochastic oscillator exited the overbought zone, and 58 of them led to successful outcomes. Odds of Success: 90%. Current price $18.48 crossed the resistance line at...
My initial thoughts on $CHRS were bullish,, but the 28% short on this low floater has dampened my bullish zeal. With a $10 range from peak to trough of this pattern, it could go big either way. Green trendline = long. Red trendline= short. Do your own due diligence!!!
This is a signal that CHRS's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. Tickeron A.I.dvisor identified 61 similar cases where CHRS's stochastic oscillator exited the overbought zone, and 52 of them led to successful outcomes. Odds of Success: 85%. Current price $17.86 crossed the resistance line at...
Trading range between ~14-18 with a new postmarket breakout to 18.35. Looking for a continuation of the breakout in pre-market.
Double bottom with a rising trend line - should be up from here
CHRS: Coherus BioSciences, Inc. 2018-11-30 09:30:00 Coherus BioSciences Announces Apexus Contract Agreement for 340B Hospitals and Clinics, and Q-Code Issuance from CMS
CHRS: Coherus BioSciences, Inc. 2018-11-02 13:41:19 U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)
Broke through resistance and pulled back today on above average volume. Will be watching for follow through tomorrow
Swingtrade based on trend-momentum and convincing price rejection a few days ago.
Signal -Potencial Short News-Earning Report- Coherus BioSciences reports 4Q loss Volumen 2.38M, Float 42.25M, Avg Vol (10 day) 780k, Avg Vol (3 month) 646k, NasdaqGM, Healthcare-Biotechnology Waiting 1 red day!!!! Potencial Short- Waiting for signal- BreakDown trend line! Break Trend line!!!! Lower-Low Waiting for opportunity! Don't leave...